Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco,...
JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a >40% reduction in risk of death, whereas Signatera-negative patients derived...
Latest findings from multicenter trial demonstrate Signatera’s ability to improve risk stratification for patients with therapy-resistant disease
Multicenter, Signatera™ Genome-guided interventional trial will evaluate different treatment approaches in HR+/HER2- breast cancer
MRD status after surgery stratifies patients beyond established clinical and genomic risk tools
Real-world Signatera™ analysis and Foresight CLARITY™ results from the HOVON study demonstrate the value of personalized ctDNA testing in therapy response assessment and surveillance
Expands Natera’s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm 1 ...
Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence